Temporal dynamics of daylight perception: Detection thresholds.

Temporal changes in illumination are ubiquitous; natural light, for example, varies in color temperature and irradiance throughout the day. Yet little is known about human sensitivity to temporal changes in illumination spectra. Here, we aimed to determine the minimum detectable velocity of chromaticity change of daylight metamers in an immersive environment. The main stimulus was a continuous, monotonic change in global illumination chromaticity along the daylight locus in warmer (toward lower correlated color temperatures [CCTs]) or cooler directions, away from an adapting base light (CCT: 13,000 K, 6500 K, 4160 K, or 2000 K). All lights were generated by spectrally tunable overhead lamps as smoothest-possible metamers of the desired chromaticities. Mean detection thresholds (for 22 participants) for a fixed duration of 10 seconds ranged from 15 to 2 CIELUV ΔE units, depending significantly on base light CCT and with a significant interaction between CCT and direction of change. Cool changes become less noticeable for progressively warmer base lights and vice versa. For the two extreme base lights, sensitivity to changes toward neutral is significantly lower than for the opposite direction. The results suggest a "neutral bias" in illumination change discriminability, and that typical temporal changes in daylight chromaticity are likely to be below threshold detectability, at least where there are no concomitant overall illuminance changes. These factors may contribute to perceptual stability of natural scenes and color constancy.

Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection.

BACKGROUND: This study investigated whether the increase in serum prostate specific antigen (PSA) typically seen during male urinary tract infection (UTI) is incidental or reflects an innate defence mechanism of the prostate. The protective roles of the whey-acid-motif-4-disulphide core (WFDC) proteins, secretory leukoproteinase inhibitor (SLPI) and WFDC2, in the prostate were also examined. METHODS: UTI recurrence was assessed retrospectively in men following initial UTI by patient interview. PSA, SLPI, and WFDC2 gene expression were assessed using biopsy samples. LNCaP and DU145 in vitro prostate cell models were utilized to assess the effects of an Escherichia coli challenge on PSA and WFDC gene expression, and bacterial invasion of the prostate epithelium. The effects of PSA on WFDC antimicrobial properties were studied using recombinant peptides and time-kill assays. RESULTS: Men presenting with PSA >4 ng/ml at initial UTI were less likely to have recurrent (r) UTI than those with PSA <4 ng/ml [2/15 (13%) vs. 7/10 (70%), P < 0.01]. Genes encoding PSA, SLPI and WFDC2, were expressed in prostatic epithelium, and the PSA and SLPI proteins co-localized in vivo. Challenging LNCaP (PSA-positive) cells with E. coli increased PSA, SLPI, and WFDC2 gene expression (P < 0.05), and PSA synthesis (P < 0.05), and reduced bacterial invasion. Pre-incubation of DU145 (PSA-negative) cells with PSA also decreased bacterial invasion. In vitro incubation of recombinant SLPI and WFDC2 with PSA resulted in peptide proteolysis and increased E. coli killing. CONCLUSIONS: Increased PSA during UTI appears protective against rUTI and in vitro is linked to proteolysis of WFDC proteins supporting enhanced prostate innate defences.